cancers treatment

New Treatment slows growth of cancers of colon, liver

harminka — Thu, 21 Jun 2007 15:29:15 -0500

Leire GarcÃƒÂa Navarro, a researcher at the School of Pharmacy of the University of Navarra, has developed a new treatment which slows the growth of colon and liver cancers.

Nanocomposite labeled cancer cells can be destroyed using lasers

harminka — Mon, 21 May 2007 03:29:46 -0500

A nanocomposite particle can be constructed so that it has a mix of properties that would not otherwise happen in nature. By combining an organic matrix with metallic clusters that can absorb light, it is possible to incorporate such particles into cells and then destroy those targeted cells with a laser.

Role of TRPM8 in the development of prostate cancer

harminka — Sat, 19 May 2007 04:35:50 -0500

Recent studies have indicated that the protein known as TRPM8 plays an important role in prostate cancer: high levels of TRPM8 have been found in prostate carcinoma compared to normal prostate epithelial cells, and TRPM8 has been suggested as a specific marker and therapeutic target in prostate cancer. However, the regulation of and changes in TRPM8 during prostate cancer progression have remained unclear.

Swedish 'snus' is linked to a doubled risk of pancreatic cancer

harminka — Thu, 10 May 2007 10:03:11 -0500

People who use Swedish moist snuff (snus) run twice the risk of developing cancer of the pancreas. This is the main result of a follow-up study conducted by Karolinska Institutet researchers amongst almost 300,000 male construction workers. The study is published today online in the prestigious medical journal The Lancet.

Dealing deadly cancers a knockout punch

harminka — Thu, 10 May 2007 07:55:28 -0500

New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers.

Animal Study Identifies New Target for Brain Tumor Therapy

harminka — Wed, 09 May 2007 08:36:43 -0500

A drug that targets the body's immune cells may be effective in treating malignant brain tumors, according to a new study led by researchers at Duke's Preston Robert Tisch Brain Tumor Center. In animal models, the drug re-engaged the body's cancer-damaged immune system.

Cancer patients monitor fatigue in real time

harminka — Fri, 04 May 2007 00:23:49 -0500

Fatigue is one of the most common and distressing symptoms cancer patients experience during chemotherapy and radiation treatment, but it's difficult for health care professionals to accurately assess its severity.

New Class of Nontoxic Cancer Treatments

harminka — Wed, 02 May 2007 07:19:31 -0500

A new class of compounds developed by two University of Kentucky researchers shows promise as a nontoxic treatment of some cancers previously treated with toxic chemotherapy, the researchers report today.

Correlation between bile duct obstruction and ductal cancer found

harminka — Mon, 30 Apr 2007 10:05:17 -0500

When bile duct cancer cells were placed in the liver of animals with bile duct obstruction, they grew more rapidly than identical cells placed in animals without bile duct obstruction. In fact, half of the total liver mass of the rats with bile duct obstruction became replaced by cancer cells within three weeks compared to only 16 percent of that of animals without bile duct obstruction.

No data to support leaving small colon polyps in place

harminka — Fri, 27 Apr 2007 07:17:52 -0500

The American Gastroenterological Association (AGA) Institute is eager to increase the number of patients who receive screening for colon cancer. There are a variety of established screening methods that are widely available, and emerging technologies, such as computed tomography colonography (CT colonography), that are under investigation.

Local Sells Affect Tamoxifen Sensitivity

harminka — Fri, 27 Apr 2007 00:02:26 -0500

Breast cancer cells that express estrogen receptor (ER) can be treated with tamoxifen only as long as they remain sensitive to the drug. Resistance to tamoxifen is a common problem in breast cancer treatment, but researchers are identifying the factors that influence sensitivity versus resistance.

Progression Of Breast Cancer

harminka — Thu, 26 Apr 2007 13:30:47 -0500

Researchers have identified loss of Fiblin-2 as a marker of breast cancer progression since the protein is expressed by normal breast cells but lost in breast cancer cell lines and invasive breast tumors. As further confirmation of Fibulin-2's anti-invasion effect, reintroduction of the protein into Fibulin-2-negative breast cancer cells resulted in decreased cell migration and invasion in vitro.